Germany’s 2026 AMNOG reform marks a significant shift in the pharmaceutical pricing and reimbursement landscape, with implications varying across products and portfolios. Launch timing, lifecycle stage, benefit rating, and other factors will play an important role in determining the impact.
Watch our recording as Simon-Kucher experts unpack the new AMNOG landscape and discuss what the changes mean for pharmaceutical companies and their pricing and reimbursement strategies.
Participants learn more about:
- Key changes to the German AMNOG pricing and reimbursement framework, including the repeal of guardrails and stricter price-volume agreements
- The new 8.5% manufacturer rebate and potential pathways for exemption
- The introduction of rebate contracting for specific patented product classes
- Implications for portfolio strategy and P&R planning, including launch timing and price (re-)negotiations
- Actions to consider for affected in-market products and future launches
